Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 29

1.

Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia.

Curtis CE, Grand FH, Musto P, Clark A, Murphy J, Perla G, Minervini MM, Stewart J, Reiter A, Cross NC.

Br J Haematol. 2007 Jul;138(1):77-81.

PMID:
17555450
[PubMed - indexed for MEDLINE]
2.

Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.

Arai A, Yan W, Wakabayashi S, Hayashi S, Inazawa J, Miura O.

Int J Hematol. 2007 Oct;86(3):233-7. Review.

PMID:
17988989
[PubMed - indexed for MEDLINE]
3.

The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.

Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutré SE.

Blood. 2004 Apr 15;103(8):2879-91. Epub 2003 Nov 20. Review.

PMID:
15070659
[PubMed - indexed for MEDLINE]
Free Article
4.

FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.

Cools J.

Verh K Acad Geneeskd Belg. 2005;67(3):169-76. Review.

PMID:
16089297
[PubMed - indexed for MEDLINE]
5.

Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.

Cross NC, Reiter A.

Acta Haematol. 2008;119(4):199-206. doi: 10.1159/000140631. Epub 2008 Jun 20. Review.

PMID:
18566537
[PubMed - indexed for MEDLINE]
6.

Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.

Coutré S, Gotlib J.

Semin Cancer Biol. 2004 Aug;14(4):307-15. Review.

PMID:
15305431
[PubMed - indexed for MEDLINE]
7.

Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome.

Stone RM, Gilliland DG, Klion AD.

Semin Oncol. 2004 Apr;31(2 Suppl 6):12-7. Review.

PMID:
15175999
[PubMed - indexed for MEDLINE]
8.

Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T6741 mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy.

Ohnishi H, Kandabashi K, Maeda Y, Kawamura M, Watanabe T.

Br J Haematol. 2006 Sep;134(5):547-9. Review. No abstract available.

PMID:
16856885
[PubMed - indexed for MEDLINE]
9.

[Oncogene Fip1-likeL/PDGFRalpha as a target for imatinib in patients with hypereosinophilic syndrome and chronic eosinophilic leukemia. A novel look at pathogenesis and therapy].

Helbig G, Stella-Hołowiecka B, Hołowiecki J.

Pol Arch Med Wewn. 2005 May;113(5):490-7. Review. Polish. No abstract available.

PMID:
16479834
[PubMed - indexed for MEDLINE]
10.

Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis.

Bain BJ.

Am J Hematol. 2004 Sep;77(1):82-5. Review.

PMID:
15307112
[PubMed - indexed for MEDLINE]
11.

The hypereosinophilic syndromes: current concepts and treatments.

Gleich GJ, Leiferman KM.

Br J Haematol. 2009 May;145(3):271-85. doi: 10.1111/j.1365-2141.2009.07599.x. Review.

PMID:
19243381
[PubMed - indexed for MEDLINE]
12.

[FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutant of PDGFRA gene: a case report and literature review].

Qu SQ, Wang Y, Sun XJ.

Zhonghua Xue Ye Xue Za Zhi. 2013 Feb;34(2):159-61. Review. Chinese. No abstract available.

PMID:
23611226
[PubMed - indexed for MEDLINE]
Free Article
13.

Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.

Coutré S, Gotlib J.

Semin Cancer Biol. 2004 Feb;14(1):23-31. Review. Erratum in: Semin Cancer Biol. 2004 Aug;14(4):306. Corrected and republished in: Semin Cancer Biol. 2004 Aug;14(4):307-15.

PMID:
14757533
[PubMed - indexed for MEDLINE]
14.

FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.

Gilliland G, Cools J, Stover EH, Wlodarska I, Marynen P.

Hematol J. 2004;5 Suppl 3:S133-7. Review. No abstract available.

PMID:
15190295
[PubMed - indexed for MEDLINE]
15.

Imatinib mesylate in the treatment of hematologic malignancies.

Piccaluga PP, Rondoni M, Paolini S, Rosti G, Martinelli G, Baccarani M.

Expert Opin Biol Ther. 2007 Oct;7(10):1597-611. Review.

PMID:
17916051
[PubMed - indexed for MEDLINE]
16.

Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants.

Roufosse F, Goldman M, Cogan E.

Semin Respir Crit Care Med. 2006 Apr;27(2):158-70. Review.

PMID:
16612767
[PubMed - indexed for MEDLINE]
17.

Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.

Yamada Y, Cancelas JA, Rothenberg ME.

Int Arch Allergy Immunol. 2009;149 Suppl 1:102-7. doi: 10.1159/000211381. Epub 2009 Jun 3. Review.

PMID:
19494514
[PubMed - indexed for MEDLINE]
18.

Milestones and monitoring in patients with CML treated with imatinib.

Deininger MW.

Hematology Am Soc Hematol Educ Program. 2008:419-26. doi: 10.1182/asheducation-2008.1.419. Review.

PMID:
19074120
[PubMed - indexed for MEDLINE]
Free Article
19.

Hypereosinophilic syndrome: diagnosis and treatment.

Peros-Golubicić T, Smojver-Jezek S.

Curr Opin Pulm Med. 2007 Sep;13(5):422-7. Review.

PMID:
17940488
[PubMed - indexed for MEDLINE]
20.

Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis.

Tefferi A, Pardanani A.

Int J Hematol. 2004 Jun;79(5):441-7. Review.

PMID:
15239393
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk